Table 1.
Baseline characteristics.
| Characteristic | ASCT (n = 3111) | Non-ASCT (n = 2437) | Total (n = 5548) |
|---|---|---|---|
| Age, median (range) at treatment initiation | |||
| Line 1 | 60 (25–77) | 73 (32–99) | 65 (25–99) |
| Line 2 | 62 (26–80) | 75 (35–102) | 68 (26–102) |
| Line 3 | 63 (34–82) | 76 (36–97) | 68 (34–97) |
| Line 4 | 63 (36–78) | 76 (37–89) | 67 (36–89) |
| MM Subtype, n (%)a | |||
| IgG | 1860 (64.3) | 1455 (59.7) | 3315 (59.8) |
| IgA | 628 (21.7) | 516 (22.8) | 1144 (20.6) |
| IgM | 6 (0.21) | 19 (0.84) | 25 (1.0) |
| FLC | 399 (13.8) | 276 (12.2) | 675 (12.2) |
| ISS Stage at diagnosis, n (%)a | |||
| I | 897 (28.8) | 389 (19.1) | 1286 (27.3) |
| II | 963 (31.0) | 748 (36.7) | 1711 (36.3) |
| III | 812 (26.0) | 902 (44.2) 1137 | 1714 (36.4) |
| Missing | 439 | 398 | 837 |
| Cytogenetics, n (%)a,b | |||
| High-risk | 587 (35.0) | 321 (28.2) | 908 (32.2) |
| Standard risk | 1092 (65.0) | 816 (71.8) | 1908 (67.) |
| Missing | 1432 | 1300 | 2732 |
aBased on evaluable patients.
bHigh risk cytogenetics based on the presence of any of deletion 17p, t(4;14), t(14;16).